ストックスクリーナーアプリを入手
45.18
0.04%
-0.02
アフターアワーズ：
45.18
前日終値:
$45.20
開ける：
$44.75
24時間の取引高:
1.23M
Relative Volume:
1.80
時価総額：
$1.95B
収益：
-
当期純損益:
$-38.99M
株価収益率:
-14.91
EPS:
-3.03
ネットキャッシュフロー:
$-24.94M
1週間 パフォーマンス:
-3.28%
1か月 パフォーマンス:
-17.60%
6か月 パフォーマンス:
+10.76%
1年 パフォーマンス:
+25.47%
1日の値動き範囲:
$44.19
$46.57
1週間の範囲:
$43.32
$48.77
52週間の値動き範囲:
$35.70
$60.92
Soleno Therapeutics Inc Stock (SLNO) Company Profile
名前
Soleno Therapeutics Inc
セクター
電話
650-213-8444
住所
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
45.18 | 1.95B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-02 | 繰り返されました | Robert W. Baird | Outperform |
| 2024-12-02 | 繰り返されました | Stifel | Buy |
| 2024-09-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-10 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-05 | 開始されました | Piper Sandler | Overweight |
| 2024-01-23 | 開始されました | Stifel | Buy |
| 2023-11-21 | 再開されました | Guggenheim | Buy |
| 2020-09-29 | 開始されました | Guggenheim | Buy |
| 2020-01-10 | 開始されました | Craig Hallum | Buy |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Soleno Therapeutics Inc (SLNO) 最新ニュース
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Soleno Therapeutics is Now Oversold (SLNO) - Nasdaq
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.11 Million Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Teachers Retirement System of The State of Kentucky Buys Shares of 13,001 Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
State Street Corp Has $57.67 Million Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
State Street Corp Buys 142,033 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - GlobeNewswire
Soleno Therapeutics Secures Massive $200M Financing Deal for Rare Disease Drug Development - StockTitan
When (SLNO) Moves Investors should Listen - Stock Traders Daily
Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me (NASDAQ:SLNO) - Seeking Alpha
Soleno Therapeutics (NASDAQ:SLNO) & Pixie Dust Technologies (NASDAQ:PXDT) Head to Head Survey - Defense World
Soleno Therapeutics' SWOT analysis: DCCR approval could reshape PWS treatment landscape By Investing.com - Investing.com South Africa
Soleno Therapeutics' SWOT analysis: DCCR approval could reshape PWS treatment landscape - Investing.com
Wellington Management Group LLP Acquires 290,135 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
FDA delays approval decision until March on DCCR for excessive hunger in PWS - Prader-Willi Syndrome News
SLNO Crosses Below Key Moving Average Level - Nasdaq
Charles Schwab Investment Management Inc. Acquires 130,080 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Prader-Willi Syndrome Market Size, Share, Industry Growth, Key - openPR
Fmr LLC Acquires 665,363 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Where are the Opportunities in (SLNO) - Stock Traders Daily
Polar Asset Management Partners Inc. Has $1.60 Million Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
What is HC Wainwright’s Estimate for SLNO FY2024 Earnings? - Defense World
What is HC Wainwright's Forecast for SLNO FY2024 Earnings? - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Bought by Janus Henderson Group PLC - MarketBeat
HighVista Strategies LLC Makes New $560,000 Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Holocene Advisors LP Increases Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Given “Outperform” Rating at Robert W. Baird - Defense World
Wainwright retains stock target, buy rating on Soleno amid FDA delay - Investing.com Nigeria
Wainwright retains stock target, buy rating on Soleno amid FDA delay By Investing.com - Investing.com South Africa
Outperform rating maintained on Soleno Therapeutics stock, regulatory approval outlook strong - Investing.com UK
Martingale Asset Management L P Purchases Shares of 21,975 Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Short Interest Down 23.2% in November - MarketBeat
Baird maintains Outperform on Soleno, keeps $72 target By Investing.com - Investing.com Australia
Baird maintains Outperform on Soleno, keeps $72 target - Investing.com
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Sold by Vestal Point Capital LP - MarketBeat
Victory Capital Management Inc. Buys 2,782 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics Receives FDA Extension for DCCR Review - Defense World
Soleno Therapeutics Inc (SLNO-Q) QuotePress Release - The Globe and Mail
PDUFA target action date for Soleno’s DCCR extended by three months - The Pharma Letter
High Growth Tech Stocks to Watch in November 2024 - Simply Wall St
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire Inc.
FDA delays decision of Soleno’s Prader-Willi syndrome drug - Yahoo Finance
What the Options Market Tells Us About Soleno Therapeutics - Benzinga
Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Wil - GuruFocus.com
FDA extends review of Soleno's Prader-Willi syndrome drug - Investing.com India
Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment - Yahoo Finance
FDA extends review of Soleno's Prader-Willi syndrome drug By Investing.com - Investing.com Nigeria
Soleno Therapeutics slides after FDA review extension of its Prader-Willi syndrome treatment - Seeking Alpha
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - The Manila Times
Soleno Therapeutics Inc (SLNO) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):